# WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

Study · id `cardio:ct-nct03302494` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03302494](<https://clinicaltrials.gov/study/NCT03302494>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03302494

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 248 participants.

## Technical summary

Registry record NCT03302494. Randomized; single masking; primary purpose prevention. Start 2017-12-27 (actual); primary completion 2023-12-21 (actual). Results posted on 2025-03-12.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 248 participants (enrolled count; ClinicalTrials.gov record NCT03302494, source copy `cardio:ctgov-nct03302494-2025-03-12`, retrieved 2026-10-26)
- Started: 2017-12-27 (actual) (ClinicalTrials.gov record NCT03302494, source copy `cardio:ctgov-nct03302494-2025-03-12`, retrieved 2026-10-26)
- Primary completion: 2023-12-21 (actual) (ClinicalTrials.gov record NCT03302494, source copy `cardio:ctgov-nct03302494-2025-03-12`, retrieved 2026-10-26)
- Completion: 2023-12-21 (actual) (ClinicalTrials.gov record NCT03302494, source copy `cardio:ctgov-nct03302494-2025-03-12`, retrieved 2026-10-26)
- Results first posted: 2025-03-12 (ClinicalTrials.gov record NCT03302494, source copy `cardio:ctgov-nct03302494-2025-03-12`, retrieved 2026-10-26)
- Countries: United States; Australia (ClinicalTrials.gov record NCT03302494, source copy `cardio:ctgov-nct03302494-2025-03-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03302494-2025-03-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2
- Acronym: WAVECREST2
- Condition: Stroke
- Intervention (Device): Coherex WaveCrest® Left Atrial Appendage Occlusion System
- Intervention (Device): Watchman® LAA Closure Device
- Lead sponsor: Coherex Medical
- Lead sponsor class: INDUSTRY
- Collaborator: Biosense Webster, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as a collaborator: Biosense Webster, Inc. (`cardio:org-biosense-webster-inc`)

## Provenance

Content hash: deddd04bb4e9000ccc4130a3cb78250c1507ee5732f044a038a4e01f8281698c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
